Plasma phosphorylated tau 181 predicts amyloid status and conversion from mild cognitive impairment to dementia stage; major impact of renal function on diagnostic performance in the BALTAZAR cohort

Authors

Sylvain Lehmann, MD PhD[1*], Susanna Schraen-Maschke, PhD[2], Jean-Sébastien Vidal, MD PhD[3], Constance Delaby, PhD[1,4], Frédéric Blanc, MD[5], Claire Paquet, MD PhD[6], Bernadette Allinquant, PhD[7], Stéphanie Bombois, MD PhD [2,8], Audrey Gabelle, MD PhD[9], Olivier Hanon, MD PhD[3*] on behalf of the BALTAZAR study group.

Affiliations

[1] LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France
[2] Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000, Lille, France
[3] Université Paris Cité, EA 4468, APHP, Hopital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, F-75013 Paris, France.
[4] Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain
[5] Université de Strasbourg, CHRU de Strasbourg, Memory Resource and Research Centre of Strasbourg/Colmar, French National Centre for Scientific Research (CNRS), ICube Laboratory and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Team Imagerie Multimodale Intégrative en Santé (IMIS)/Neurocrypto, F-67000 Strasbourg, France.
[6] Université Paris Cité, GHU APHP Nord Lariboisière Fernand Widal, Centre de Neurologie Cognitive , F-75010 Paris, France.
[7] UMR-S 1266, Université Paris Cité, Institute of Psychiatry and Neurosciences, Inserm, Paris, France
[8] Assistance Publique-Hôpitaux de Paris (AP-HP), Département de Neurologie, Centre des Maladies Cognitives et Comportementales, GH Pitié-Salpêtrière, Paris, France.
[9] Université de Montpellier, CHRU Montpellier, Memory Research and Resources center, department of Neurology, Inserm INM NeuroPEPs team, excellence center of neurodegenerative disorders, F-34000 Montpellier, France.

* Corresponding authors

Pr Sylvain Lehmann, CHU and University of Montpellier, 80 av Fliche, 34295 Montpellier, France, E-mail : s-lehmann@chu-montpellier.fr, Tel: +33 (0)4 67 33 71 24

Pr Olivier Hanon Olivier Hanon, Hopital Broca, 54-56 rue Pascal, Paris 75013, France. E-mail: olivier.hanon@aphp.fr, Tel: +33 (0)1 44 08 33 81;

Abstract

Background

Plasma P-tau181 is associated with tau and amyloid pathology in Alzheimer's disease (AD). Its use as a biomarker for the detection of AD (along the disease continuum, from preclinical to mild cognitive impairment (MCI) and dementia) is increasingly established, as is its prognostic value. Further validation in different settings of use is still needed, as well as investigation of confounding factors that might indirectly influence its blood concentration.

Methods

This study is ancillary to the prospective multicenter BALTAZAR cohort that enrolled patients with MCI according to Petersen criteria. Amyloid-positive (Aβ+) status was based on assessment of the cerebrospinal fluid (CSF) Aβ1-42/Aβ1-40 ratio, and participants were examined for conversion to dementia for up to three years. Plasma Ptau-181 was measured using an ultrasensitive assay and its diagnostic performance for Aβ+ and conversion to dementia were studied, as well as evaluation of the impact of comorbidities and biological confounders.

Findings

Among 476 MCI participants (mean MMSE score of 26·4 [SD 2·5] and 39·8% carrying APOE ε4), 67% were Aβ+ and 30% developed dementia (95% probable AD) at a mean of 14·6 [SD 8·2] months after the baseline. Independently of age, sex, and APOEε4, plasma P-tau181 was increased significantly by 30% between non-converters and converters (2·9 [SD 1·4] vs. 3·8 [SD 1·5] pg/mL, $p<0·0001$) and by 50% between Aβ- and Aβ+ (2·6 [SD 1·4] vs. 3·9 [SD 1·4] pg/mL, $p<0·0001$). Logistic regression was used to compare conversion and Aβ+ detection combining age, sex, APOEε4 status and MMSE without or with the addition of plasma P-tau181 which significantly improves performance (AUC 0·691 to 0·744 for conversion and 0·786 to 0·849 for Aβ+). CSF P-tau181 did not perform better in the same setting. Using a linear regression approach, chronic kidney disease (CKD), creatinine and glomerular filtration rate were independently associated with plasma P-tau181 concentrations, thereby altering the optimal cutpoints for Aβ+ or conversion to dementia detection.

Interpretation

Plasma P-tau181 effectively detects Aβ+ and conversion to dementia in a manner similar to CSF P-tau181, making this blood biomarker central to AD management. However, renal function significantly alters concentrations and will induce diagnostic error if not systematically taken into account.

Introduction

Alzheimer's disease (AD), which accounts for 60% to 70% of dementia, is a major public health problem because of its prevalence, which is increasing with the ageing of the population, and the socio-economic burden it represents. For a long time, the diagnostic effort has been minimized due to the lack of preventive measures or curative treatment. However, in recent years, it has been demonstrated that modifiable risk factors account for 40% of AD [1], In addition, many potential treatments are in the final stages of study [2], which gives us great hope of having disease-modifying treatments that will be all the more effective the earlier they are prescribed.

The development of biological biomarkers linked to amyloid and tau pathology has greatly contributed to the understanding of the so-called AD "continuum" in which, thanks to genetic forms, it has been shown that the disease was present from a biological point of view decades before its clinical appearance [3]. This, in addition to opening up therapeutic perspectives, allows us to use these biomarkers in early diagnosis and even in risk assessment. Their relevance has already been proven in cerebrospinal fluid (CSF) justifying their implementation in clinical routine [4,5]. Thanks to ultrasensitive assays and mass spectrometry approaches, blood amyloid peptides were the first to show a significant detection of amyloid positive (Aβ+) patients as defined by amyloid PET or CSF analysis or to predict evolution of patients within the AD continuum, including conversion of patients with a mild cognitive impairment (MCI) to dementia [6]. While the detection of total tau in blood was not so discriminating [7], the ability to detect its phosphorylated forms at position threonine 181 (P-tau181) was a real breakthrough [8]. Its concentration is predictive of amyloid or tau PET findings and is significantly higher in AD and MCI compared to subjects without cognitive impairment or compared to other causes of dementia [8-10]. Its prognostic value has also been established in some longitudinal studies [11-13] and its overall performance is consistent with real-life clinical application. To reach this milestone, we will need additional prospective data, *in vitro* diagnostic (IVD) certified kits, sufficient information on preanalytical stability and also identification of possible confounding factors that may alter clinical performance in routine use.

In this work, we used the prospective multicenter BALTAZAR cohort [14] to confirm the ability of plasma P-tau181 to detect the presence of brain amyloidopathy and, in addition, to predict the conversion of MCI patients (evaluated primarily in memory centers) to dementia stage. As

plasma biomarkers are about to be implemented in routine practice, we also investigated potential confounding factors that need to be considered to interpret the results adequately.

Materials and Methods

Study population

The BALTAZAR (Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk) study is a multicenter prospective cohort study (ClinicalTrials.gov Identifier #NCT01315639) that enrolled patients with MCI or AD according to a previously described protocol [14]. All the participants underwent clinical, neuropsychological, brain MRI and biological assessments (see below). Right and left hippocampal volume was obtain for each participant using automatic segmentation of the hippocampus. The hippocampal volume was normalized using the following calculation: hippocampal volume/total brain volume × mean total brain volume. CSF samples were collected only in accepting participants. APOE was genotyped in a single centralized laboratory. MCI subjects were selected according to the Petersen' criteria [15] and then were dichotomized into amnestic (aMCI) and non-amnestic (naMCI) phenotypes based on the presence of memory impairment on the free and cued selective reminding test related to age, sex and educational level. The characteristic of the aMCI/naMCI population is fully described elsewhere[14]. Patient underwent visits every six months for three years. MCI participants were reassessed for conversion to dementia at each visit by the clinician [6]. The progression from MCI to dementia was defined by evaluation of the following parameters: decline in cognitive functioning (measured by changes from the baseline in scores of the mini mental state examination [MMSE]), and disability in activities of daily living (instrumental activities of daily living iADL>1 and clinical dementia rating sum of boxes ($\geq$ 1). The conversions were reviewed by an adjudication committee.

In this study, we analyzed 476 available baseline plasma samples from patients with MCI diagnosis (365 aMCI and 111 naMCI).

Biological biomarker measurements

To minimize pre-analytical and analytical problems, identical collection tubes were used across centers to collect plasma (EDTA BD Vacutainer K2E, ref 367 525, Becton Dickinson, USA) and for CSF (10mL polypropylene tube, ref 62·610·201, Sarstedt, Germany). All plasma and CSF aliquots were stored in the same low binding Eppendorf® LoBind microtubes (Eppendorf, ref

022431064, Hamburg, Germany). Blood samples taken at baseline were used to measure fasting glycemia, cholesterol (total, HDL, LDL), prealbumin, albumin, creatinine [14]. Estimated glomerular filtration rate (eGFR) based on creatinine, age and sex was computed using the CKD-Epidemiology Collaboration (CKD-EPI) equation [16]. CSF biomarkers were measured in a single centralized laboratory using commercially available Innotest® assays for tau and phosphorylated tau at position T181 (P-tau181) or Euroimmun® for amyloid peptides Aβ1-42 and Aβ1-40· Positive amyloid status (Aβ+) was defined when CSF Aβ1-42/Aβ1-40 ratio was below 0·1 as previously reported [17].

Plasma P-tau181 was determined using commercial P-tau181 assay kit (Quanterix, USA) based on ultrasensitive Simoa technology [18] on an HD-X analytical platform. All samples were 4-fold diluted with the provided dilution buffer to minimize matrix effects. Following dilution, the lowest limit of detection was 0·019 pg/mL and the limit of quantification was of 0·085 pg/mL. Quality controls with low P-tau181 concentration (QC 1 with mean concentration of 3·82 pg/mL) and QC high P-tau181 known concentration (QC 2 with mean concentration of 52·4 pg/mL) were provided in the kits. Inter-assay variation for QC 1 and QC 2 was low, with coefficient of variation (CV) of 7% and 5%, respectively. We also added two internal QC (high and low) with pooled serum (mean P-tau181 of 4·47 pg/mL et 2·81 pg/mL) to be analysed at the start and end of each sample plate, which displayed a low inter-assay CV of 3% and 6%, respectively.

Statistical analyses

General characteristics were analyzed in the whole MCI sample, according to MCI subtype (aMCI and naMCI), to conversion to dementia and to tertile of plasma P-tau181 values. Categorical variables are presented as percentage and counts (% (N)), continuous variables as mean and standard deviation (M (SD)) or median [25-75 percentile] and comparison were made with χ^2 tests, T-tests, Mann-Whitney and analysis of variance (ANOVA, Kruskal-Wallis test). The relationship between conversion and plasma P-tau181 was using with regression models with conversion as dependent variables, plasma P-tau181 as independent variables adjusted for age, sex, and presence of APOE ε4 allele at baseline. Kaplan Meier curves were drawn for conversion according to tertile plasma P-tau181 and overall difference between the tertile was calculated with Log rank test. We also examined how plasma P-tau181 improved dementia risk prediction using logistic regression with age, sex, APOE ε4 and MMSE score at baseline and by calculating continuous net reclassification improvement (NRI) [19]. Receiving Operator

Characteristic (ROC) curves using conversion as a dependent variable were also used to compute for different factors the area under the curve (AUCs) that were compared using the Delong method [20]. Logistic regression model (enter model), Kaplan Meier and ROC curves were performed with the MedCalc (20·111) software program. All analyses other were done using R software (R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/). In all analyses, the 2-sided α-level of 0·05 was used for significance testing.

Role of the funding source

They had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication

Results

Characteristics of the MCI participants at baseline

Of the 539 MCI participants enrolled in the BALTAZAR study, 63 were excluded due to missing data and absence of plasma P-tau181 biomarkers. In this study, we analyzed, 476 MCI participants (mean age 77·7 [SD 5·5] years, 61·4% women) with 365 aMCI (77%) and 111 naMCI (23%) at baseline (Table 1, Suppl Table 1). Average MMSE score was 26·4 [SD 2·5] and 39·8% (n=185) were APOE ε4 carriers. During the clinical follow-up period of 6 to 36 months, 30% (n=144) of the MCI participants developed dementia on average 14·6 [SD 8·2] months after the baseline visit and in 95% of the cases, they converted to clinically probable AD [6].

Comparison between MCI converters and non-converters

As already reported in BALTAZAR [6] and illustrated in Table 1, at baseline, the MCI converters to dementia were older, had a lower MMSE score, were more often APOE ε4 carriers and had more severe hippocampal atrophy. CSF Aβ1-40, Aβ1-42, Tau and p-Tau181 values available in a part of the MCI population (n= 214; as lumbar puncture was optional) were also highly differential between MCI that converted or not. We have previously described that plasma amyloid biomarkers measured with an early generation of assay in the BALTAZAR cohort [6] showed differential level. More interestingly, plasma P-tau181 increased significantly on average by 30% between MC non-converters at 2·9 [SD 1·4] pg/mL and converters at 3·8 [SD 1·5] pg/mL (p<0·0001). All these results remained significant after adjustment for age, sex, and the APOE ε4

status (Table 1). At the opposite, no difference was observed between MCI converters and non-converters for metabolic or renal function blood biomarkers represented by fasting blood glucose (glycemia), triglycerides, cholesterol (total, HDL, LDL), prealbumin, albumin and creatinine or glomerular filtration rate [16] (eGFR).

Comparison between Aβ+ and Aβ- patients

The amyloid status Aβ+ corresponding to the (A+) ATN classification [3] was defined based on the CSF Aβ1-42/Aβ1-40 ratio as previously reported [21]. Only part of MCI participants had a lumbar puncture and 117 of them were Aβ+ and 97 Aβ-. At baseline, Aβ+ population was older, had a lower MMSE score, were more often APOE ε4 carriers but, unlike MCI converters, they did not have a lower hippocampal volume (Table *2*). CSF Aβ1-42, Tau and p-Tau181 values were also highly differential between these groups. Metabolic blood biomarkers and eGFR were not different. Plasma P-tau181 significantly increased on average by 50% between Aβ- and Aβ+ (2·6 [SD 1·4] vs. 3·9 [SD 1·4] pg/mL, p<0·0001). All these results remained significant after adjustment for age, sex, and the APOE ε4 status (Table *2*).

Combination of plasma or CSF P-tau181 with age, sex, APOEε4 status and MMSE for MCI conversion and amyloid status detection

Using a logistic regression approach with conversion as a dependent variable, and age, sex, APOEε4 status and MMSE as independent variables, it was possible to predict conversion (P <·0001) with an AUC of the model fit of 0·691 [95%CI=0·655-0·741]. The addition of plasma P-tau181 resulted in an significant increase of the AUC to 0·744 [95%CI=0·702-0·784] (Suppl Table 3). The added value of plasma P-tau181 was further documented by computing the NRI of the two models that resulted in a 12·8% of patient's classification improvement between MCI converters and non-converters. The comparison of the respective values of plasma and CSF P-tau181 was investigated in the same way for amyloid status detection in the sub-cohort where patients had undergone a lumbar puncture. The addition in the model of plasma or CSF P-tau181 resulted in a significant increase of the AUC from 0·786 [95%CI=0·723-0·84] for age, sex, APOEε4 status and MMSE to 0·849 [95%CI=0·792-0·895] and 0·857 [95%CI=0·801-0·902], respectively (P[difference]=0·00075 and 0·0002). AUCs obtained by the addition of plasma or CSF P-tau181 for conversion or amyloid status detection (0·750 and 0·752, respectively) were not different (P[difference]=·81).

Correlation and differences between tertile of plasma P-tau181

The relationships and correlations between plasma P-tau181 concentration and the other biomarkers and cohort characteristics were analysed after splitting the population by tertile (Table 3). Age, body mass index (BMI) and APO ε4 were significantly different between tertile. Patient conversion rate was also clearly differentials with values of 16·4%, 26·1% and 47·8% in the 1st, 2nd and 3rd tertile, respectively. Distribution of Aβ+ patients was also greatly increased along with tertile, a relationship that was confirmed by the high correlation observed between plasma P-tau181 and CSF Aβ1-42/Aβ1-40 (correlation coefficient = -0·4428, p<0·0001). eGFR decreased (p=0·017) while creatinine very significantly increased (p<·0001) along with plasma P-tau181 tertile. All these results remained significant after adjustment for age, sex, and the APOE ε4 status (Table 3). The relationship between plasma P-tau181 and MCI conversion was further documented by plotting the Kaplan–Meier curve of conversion to dementia according to the tertiles (Figure 1A). A very significant overall difference was observed (Log rank P<·0001) and the hazard ratio (HR) between the 1st and the 3rd tertile was 3·8 [95%CI=2·5-5·8].

Impact of comorbidities and covariates on P-tau181 concentration and diagnostic performance

The relationship between plasma P-tau181 concentration and comorbidities, demographic factors and biological information collected at baseline in the BALTAZAR cohort was investigated using a linear regression approach [22,23]. APOE status, creatinine and eGFR could be identified as impacting the most plasma P-tau181 (Figure 1B). We found also at a lower extent, age and BMI affecting plasma P-tau181levels. Among comorbidities, chronic kidney disease (CKD) had the most pronounce effect. All these results remained very similar after adjustment for age, sex, and the APOE ε4 status. To further evaluated the impact of these covariates, we plotted the correlation between creatinine, eGFR, BMI and age in the population stratified by the amyloid status (Figure 2A-D). The correlation in the BALTAZAR subpopulation with lumbar puncture (n=214) remained significant only for eGFR and creatinine (Suppl Table 2). We observed higher values of plasma P-tau181 in the Aβ+ population but at the same time, levels were also different in low and high values of eGFR and creatinine, particularly. To confirm this observation, we stratified the population based on tertile of creatinine or eGFR levels (Figure 2EF, Table 4). The analysis of variance confirmed that the mean of plasma P-tau181 was globally differential among

tertiles (p<0·001). To evaluate the impact on the detection of amyloid status detection, we computed the ROC curves and determined cutpoints based on the Youden index, as well as the corresponding performance for Aβ+ (Table 4).

Discussion

In this large-scale multicenter prospective longitudinal cohort of clinically defined MCI referred to memory center, with a follow-up of three years, a patient who converted to dementia had higher values by 30% of plasma P-tau181 independently of age, sex or APOE ε4. Importantly, 48% of MCI participants among the highest tertile of plasma P-tau181 (>3·61) converted to dementia and had a risk increased by four times. In this MCI population, the amyloid status of patients based on the CSF Aβ1-42/Aβ1-40 ratio was also significantly differentiated by plasma P-tau181, with Aβ+ patients showing a 50% higher concentration compared with their Aβ-counterpart.

One important element that raises the interest of using of these plasma biomarkers in the future is its added values when compared to a combination of age, sex, APOEε4 status and MMSE. It is noteworthy that adding plasma P-tau181 significantly improved the detection of both Aβ+ patients and MCI converters. What was even more striking is that this added value of plasma P-tau181 was equivalent to that of CSF P-tau181· This finding has an important value for a future use of the approach in clinical routine, may be avoiding the need for a lumbar puncture.

The capacity of plasma P-tau181 to detect Aβ+ patients as well as AD and MCI when compared to control and to other diseases has also been well described [8,9,11-13,24-27]. One study showed that plasma P-tau181 improved prediction of cognitive decline in MCI and AD [12], and a large study in 560 MCI and 221 AD patients [13] confirmed the increased level at baseline for both conditions, and a faster increase in longitudinal follow-up. The only study comparable to our work, is to our knowledge, that of Karikari et al. in the Alzheimer's Disease Neuroimaging Initiative [11]. Comparing cognitively unimpaired, MCI and AD patients the authors also observed that baseline concentrations of plasma P-tau181 accurately predicted future dementia and Aβ+ status as defined by PET.

One important added value of our study is the consideration of the biological information collected in the BALTAZAR cohort. In fact, metabolic blood biomarkers represented by fasting glycemia, triglycerides, cholesterol (total, HDL, LDL), prealbumin, albumin, creatinine and

eGFR were available as a way to monitor diabetes, cardiovascular risk, nutritional status or kidney function. When MCI converters and non-converters, as well as Aβ+ and Aβ- patients where compared none of these factors were differential. When we investigated factors influencing P-Tau181 level by comparing tertiles or through a linear regression method, we first identified age and BMI as cofounding factors. These two factors have been identified before not only for P-Tau181 but also for other blood biomarkers like neurofilaments [28]. Age increases not only plasma but also CSF values of neurodegenerative biomarkers like total tau [29] without yet a definitive explanation of the phenomenon. For BMI the rational is related to the dilution of neuronal biomarker in the blood volume, itself correlated to BMI. Among comorbidities, CKD was the most differential, an association that was already reported in recent studies [22,23]. In BALTAZAR we have access to the clinical chemistry profile of the patient realized on the same plasma sample used for P-tau181 measurement. Creatinine and eGFR that both reflect kidney function were also strongly associated to P-tau181 concentration. When we investigated the impact of age, BMI, creatinine and eGFR on plasma P-Tau181 performance for the detection Aβ+ patients, only creatinine and eGFR had a significant impact. Namely, in situations with increased creatinine (>=82) or low eGFR (<74), indicating a moderate impaired kidney function, levels of P-Tau181 were increased in both Aβ+ and Aβ- patients, as well as in MCI patients converting or not to dementia. The consequence is a modification of the optimal clinical cutpoints, as illustrated in detail for the detection of the amyloid status. This observation is very important, and we advocate minimizing the false detection of a pathological situation in patients by always combining plasma P-Tau181 with an assessment of renal function, e.g., through creatinine measurement and GFR estimation. This recommendation should be confirmed for other P-Tau isoforms (P-Tau217, P-Tau231) measured by immunoassay [25] or mass spectrometry [30]. The clearance of P-Tau by the kidney will have to be studied in more detail, taking into account our knowledge of the urinary excretion of protein in physiological and pathological conditions [31] and the very small amounts of this biomarker detected so far in the urine in free form [32] or associated with exosomes [33].

The present study has some limitations. In order to increase the likelihood of conversion to AD we excluded participants with Lewy Body, Parkinson, frontotemporal or vascular MCI disorders. Therefore 77% of subjects had amnestic form of MCI and 30% of participants developed dementia which in 95% of cases was represented by probable AD. Amyloid status was available

only in part of the population, since BALTAZAR study focused on conversion, and it was defined using CSF biomarkers rather than with PET amyloid.

The main strengths of the study lie in the large sample size of MCI participants that are well described, the controlled pre-analytical conditions, the centralized plasma P-tau181 analyses and the availability of clinical chemistry analyte measurement realized in the same sample tube.

Conclusion

Our study in this well-characterized population confirms, on the one hand, the clinical relevance of plasma P-tau181 for the detection of amyloid status, which is important for risk assessment, patient management and inclusion in clinical trials. On the other hand, we showed the strong predictive value of this blood biomarker for the prognosis of MCI patients, an important issue that addresses a medical need in memory centers. Finally, we identified and quantified the impact of renal function, assessed by creatinine levels and GFR estimation, on P-tau181 blood levels, which is essential information to ensure a good interpretation of the results in routine clinical practice.

Statements

Funding information

The French ministry of Health (Programme Hospitalier de Recherche Clinique), Grant/Award Numbers:PHRC2009/01-04,PHRC-13-0404; The Foundation Plan Alzheimer; Fondation pour la Recherche Médicale (FRM).

Author contributions

S.L., J.S.V. and O.H. take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: O.H., S.B., A.G., S S-M., S.L.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: S.L.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: S.L., J.S.V.

Obtained funding: O.H., S.B., A.G., S S-M., S.L.

All authors had full access to the data and contributed to revision and editing of the manuscript.

Data Sharing

Data and informed consent form are available upon request after publication (APHP, Paris). Requests will be considered by each study investigators based on the information provided by the requester regarding the study and analysis plan. If the use is appropriate, a data sharing agreement will be put in place before a fully de-identified version of the dataset including the data dictionary used for analysis with individual participant data is made available.

Conflict of interest statement

The authors report no conflict of interest related to the present manuscript.

Ethical statement

All participants gave written informed consent to be part of the study. The BALTAZAR study was approved by the Paris ethics committee (CPP Ile de France IV Saint-Louis Hospital).

Research in context

Evidence before this study

The detection of blood biomarkers related to brain amyloid and tau pathology and capable of predicting the progression of patients along the Alzheimer's disease continuum represents a major advance and foreshadows a future revolution in patient management. Before real-life clinical application, we will need additional prospective data and identification of possible confounding factors that could alter clinical performance in routine use.

Added value of this study

In this work, we were able to study in a large, prospective, multicenter longitudinal cohort the value of plasma phosphoph-tau181 in detecting the presence of brain amyloidopathy and conversion of patients with mild cognitive impairment to dementia. We were also able to investigate potential confounding factors (comorbidities) that need to be considered to adequately interpret the results.

Implications of all the available evidence

The clinical relevance of P-tau181 plasma for the diagnosis and prognosis of patients with mild cognitive impairment is confirmed, paving the way for its use in real life. We also identified and quantified the impact of renal function, assessed by creatinine levels and GFR estimation, on P-tau181 blood levels, which is essential information to ensure a good interpretation of the results in routine clinical practice.

Keywords

Blood biomarkers, Alzheimer, amyloid status, conversion to dementia, phosphorylated tau, kidney function

Tables

Table 1: Characteristics in the whole MCI population and between MCI that converted or not to dementia within 3 years

Patient characteristics	All MCI N=476	MCI Non-converters N= 332	MCI converters N=144	P	P$
Age (years)	77·7 (5·5)	77·3 (5·4)	78·5 (5·7)	**·048**	**·0033**
Women (%)	292 (61·4)	205 (61·7)	60·4	·78	·67
BMI (kg/m2)	25 (3·8)	25·1 (3·8)	24·8 (3·8)	·39	·95
MMSE (/30)	26·4 (2·5)	26·7 (2·5)	25·6 (2·5)	**<·0001**	**·0002**
1 or 2 APOE4 alleles	185 (39·8)	105 (31·6)	80 (55·5)	**<·0001**	**<·0001**
Hippocampal volume (R+L) (cm3)	4·55 (1·12)	4·79 (1·05)	4·01 (1·09)	**<·0001**	**<·0001**
CSF biomarkers*	All MCI	MCI Non-converters	MCI converters	P	P$
Aβ1-40 (pg/mL)	7434 (2241)	7458 (2298)	7389 (2143)	·83	·64
Aβ1-42 (pg/mL)	766 (384)	857 (398)	593 (288)	**<·0001**	**<·0001**
Aβ1-42/Aβ1-40	0·104 (0·045)	0·116 (0·045)	0·082 (0·036)	**<·0001**	**<·0001**
Tau (pg/mL)	578 (254)	376,1 (185,2)	547 (223,4)	**<·0001**	**<·0001**
p-Tau181 (pg/mL)	76·7 (30·2)	58,58 (24,47)	80,3 (33,58)	**<·0001**	**<·0001**
Blood biomarkers	All MCI	MCI Non-converters	MCI converters	P	P$
Fasting glycemia (mmol/L)	5·37 (1·19)	5·34 (1·21)	5·45 (1·14)	·34	·20
Triglycerides (mmol/L)	1,21 (0,59)	1,2 (0,58)	1,24 (0,6)	0,54	·82
Cholesterol total (mmol/L)	5,5 (1,16)	5,48 (1,2)	5,53 (1,07)	·67	·91
Cholesterol HDL (mmol/L)	1,74 (0,52)	1,75 (0,53)	1,72 (0,48)	·66	·98
Cholesterol LDL (mmol/L)	3,2 (1)	3,19 (1,01)	3,24 (0,98)	·65	·90
Prealbumin (mg/dL)	27·6 (5·4)	28·1 (6·2)	27·7 (5·8)	·53	·52
Albumin (g/L)	40·3 (3·9)	40·5 (3·5)	39·8 (4·5)	·088	·11
Creatinine (μmol/L)	78·2 (21·3)	79·4 (22·2)	73·7 (13·6)	·10	·82
eGFR (mL/min/1·73m2)	76·9 (14·7)	77·0 (14·8)	76·7 (14·7)	·85	·80
Plasma P-tau181(pg/mL)	3·19 (1·49)	2·9 (1·4)	3·8 (1·5)	**<·0001**	**<·0001**

Abbreviations: MCI: mild cognitive impairment; APOE: apolipoprotein E; BMI, body mass index; eGFR, estimated glomerular filtration rate; MMSE, Mini–Mental State Examination; R+L, right+left.

P: Comparison between the three groups, with ANOVA or χ2; P$: comparison between the three groups with linear regression adjusted for age, sex, and the presence of the APOE ε4 allele; % (number) were used to describe categorical variables. mean ± standard deviation for continuous variables.
* CSF biomarkers were available only in 140 and 74 MCI non-converters and converters, respectively.

Table 2: Characteristics in the whole population and between Aβ- and + patients

Patient characteristics	All N=214	Aβ- N= 97	Aβ+ N=117	P	P$
Age (years)	77·4 (5·6)	76·6 (5·1)	78 (5·9)	·073	**·0122**
Women (%)	127 (59·3)	53 (54·6)	74 (64·9)	·20	·36
BMI (kg/m2)	24·7 (3·7)	25·4 (3·7)	24·2 (3·6)	**·024**	·26
MMSE (/30)	26·4 (2·4)	27·1 (2)	25·8 (2·5)	**<·0001**	**0·0007**
1 or 2 APOE4 alleles	78 (36·4)	15 (15·5)	63 (57·3)	**<·0001**	**<·0001**
Hippocampal volume (R+L) (cm3)	4·56 (1·09)	4·64 (1·23)	4·5 (0·96)	·41	·91
CSF biomarkers*	All	Aβ-	Aβ+	P	P$
Aβ1-40 (pg/mL)	7434 (2241)	7421 (1896)	7446 (2499)	·93	·62
Aβ1-42 (pg/mL)	766 (385)	1095 (287)	494 (196)	**<·0001**	**<·0001**
Aβ1-42/Aβ1-40	0·104 (0·045)	0·149 (0·022)	0·068 (0·018)	**<·0001**	**<·0001**
Tau (pg/mL)	433 (213)	320 (133)	533 (222)	**<·0001**	**<·0001**
p-Tau181 (pg/mL)	66·4 (30·2)	51·3 (15·1)	79 (33·8)	**<·0001**	**<·0001**
Blood biomarkers	All	Aβ-	Aβ+	P	P$
Fasting glycemia (mmol/L)	5·4 (1·1)	5·4 (1·1)	5·4 (1·2)	·99	·71
Triglycerides (mmol/L)	1·17 (0·6)	1·18 (0·48)	1·15 (0·69)	·70	·62
Cholesterol total (mmol/L)	5·5 (1·2)	5·5 (1·3)	5·5 (1·1)	·78	·29
Cholesterol LDL (mmol/L)	1·7 (0·5)	1·8 (0·5)	1·7 (0·5)	·58	·81
Cholesterol HDL (mmol/L)	3·2 (1)	3·3 (1·1)	3·2 (0·9)	·92	·21
Prealbumin (mg/dL)	28·4 (6·4)	28·5 (7·6)	28·3 (5·1)	·77	·77
Albumin (g/L)	40·1 (4·3)	39·9 (3·6)	40·2 (4·9)	·60	·38
Creatinine (µmol/L)	79·0 (23·0)	80·1 (24·9)	78·2 (21·5)	·54	·76
eGFR (mL/min/1·73m2)	76·9 (14·7)	76·9 (15·5)	77·5 (15·5)	·62	·45
Plasma P-tau181 (pg/mL)	3·3 (1·5)	2·6 (1·4)	3·9 (1·4)	**<·0001**	**<·0001**

Abbreviations: MCI: mild cognitive impairment; MCI, APOE: apolipoprotein E; BMI, body mass index; eGFR, estimated glomerular filtration rate; MMSE, Mini–Mental State Examination; R+L, right+left.

P: Comparison between the three groups, with ANOVA or $\chi 2$); P$: comparison between the three groups with linear regression adjusted for age, sex, and the presence of the APOE ε4 allele; % (number) were used to describe categorical variables. mean ± standard deviation for continuous variables.

* CSF biomarkers were available only in 152 and 76 MCI non-converters and converters, respectively.

Table 3: Characteristics in the different P-tau181 tertiles

Plasma P-tau181	1st tertile N= 158	2nd tertile N= 157	3rd tertile N=161	P	P$
Age (years)	76·9 (5·4)	77·9 (5·1)	78·3 (5·9)	·062	**·0009**
Women (%)	101 (63·9)	96 (61·1)	95 (59·0)	·66	·32
BMI (kg/m2)	25·8 (3·7)	24·9 (3·9)	24·4 (3·7)	**·0037**	**·0097**
MMSE (/30)	26·7 (2·4)	26·4 (2·5)	26·1 (2·7)	·16	·19
1 or 2 APOE4 alleles (%)	38 (17·7)	63 (40·1)	84 (52·2)	**<·0001**	**<·0001**
Hippocampal volume (R+L) (cm3)	4·75 (1·13)	4·38 (1·16)	4·5 (1·04)	·0227	·28
Aβ+ status (%)	13 (19,1)	40 (62·5)	64 (78·0)	**<·0001**	**<·0001**
Conversion MCI (%)	26 (16·4)	41 (26·1)	77 (47·8)	**<·0001**	**<·0001**
Blood biomarkers	1st	2nd	3rd	P	P$
Fasting glycemia (mmol/L)	5·46 (1·28)	5·4 (1·1)	5·26 (1·18)	·32	·12
Triglycerides (mmol/L)	1,2 (0,6)	1,3 (0,7)	1,2 (0,5)	0,2584	0,2300
Cholesterol (mmol/L)	5,52 (1,19)	5,48 (1,23)	5,5 (1,06)	0,9444	0,8179
Cholesterol HDL (mmol/L)	1,72 (0,47)	1,76 (0,56)	1,75 (0,52)	0,8536	0,2929
Cholesterol LDL (mmol/L)	3,25 (1,03)	3,15 (1,07)	3,21 (0,9)	0,6894	0,5858
Prealbumin (mg/dL)	27·5 (6·2)	28 (6·7)	28·4 (5·4)	·47	·17
Albumin (g/L)	40·4 (3·7)	40·2 (4·8)	40·3 (3·1)	0·87	·90
Creatinine (μmol/l)	73·5 (16·5)	78·6 (19)	82·1 (26·1)	**·002**	**·0005**
eGFR (mL/min/1·73m2)	80·3 (13·5)	76 (14·1)	74·4 (15·9)	**·017**	**·012**
Plasma P-tau181(pg/mL)	1·75 (0·38)	2·93 (0·36)	4·86 (1·19)	**<·0001**	**<·0001**

Abbreviations: MCI: mild cognitive impairment; APOE: apolipoprotein E; BMI, body mass index; eGFR, estimated glomerular filtration rate; MMSE, Mini–Mental State Examination; R+L, right+left.

P: Comparison between the three groups, with ANOVA or χ2); P$: comparison between the three groups with linear regression adjusted for age, sex, and the presence of the APOE ε4 allele; % (number) were used to describe categorical variables. mean ± standard deviation for continuous variables.

Table 4: Performance of plasma P-tau181 for Aβ+ detection with regard to renal function (creatinine and eGFR)

Population with CSF biomarkers available	Total	Creatinine < 68 1st tertile	Creatinine 69-82 2nd tertile	Creatinine>=82 3rd tertile
Creatinine (µmol/l)	74 [71-77]	61 [57-64]	73 [71-80]	95 [84-111]
Plasma P-tau 181(pg/mL)	3·0 [2·8-3·4]	2·3 [1·8-3·3]	2·9 [2·5-3·9]	3·7 [2·7-5·2]
Plasma P-tau 181 in Aβ-	2·2 [1·9-2·4]	1·9 [1·5-2·4]	2·3 [1·6-2·7]	2·9 [1·9-4·0]
Plasma P-tau 181 in Aβ+	3·7 [2·8-4·5]	3·1 [2·2-4·3]	3·6 [2·9-4·0]	4·2 [3·6-5·4]
AUC Plasma P-tau 181 Aβ+	0·783	0·763	0·872	0·733
Plasma P-tau 181 cutpoints (pg/mL)	2·77	2·31	2·77	3·52
Sensibility (%)	80·9	75·0	89·5	80·0
Specificity (%)	69·6	73·0	80·0	70·0
Population with CSF biomarkers available	Total	eGFR < 74 1st tertile	eGFR 74-86 2nd tertile	eGFR >86 3rd tertile
eGFR (mL/min/1·73m2)	79 [68-89]	64 [54-69]	79 [76-84]	91 [89-93]
Plasma P-tau 181(pg/mL)	3·0 [2·1-3·9]	3·5 [2·4-4·2]	3·1 [2·1-3·9]	2·7 [1·8-3·9]
Plasma P-tau 181 in Aβ-	2·2 [1·7-3·0]	2·7 [1·7-3·4]	2·0 [1·7-2·6]	2·0 [1·6-2·9]
Plasma P-tau 181 in Aβ+	3·7 [2·8-4·5]	3·8 [3·1-5·4]	3·8 [2·8-4·5]	3·3 [2·7-4·2]
AUC Plasma P-tau 181 Aβ+	0·783	0·763	0·872	0·733
Plasma P-tau 181 cutpoints (pg/mL)	2·77	2·81	2·71	2·44
Sensibility (%)	80·9	86·4	84·2	78·8
Specificity (%)	69·6	60·0	77·8	68·6

Abbreviations: CSF: cerebrospinal fluid; AUC: area under the ROC curve; eGFR, estimated glomerular filtration rate.

Values of creatinine and plasma P-tau181 are express as median [25-75 percentile]. Cutpoints correspond to the best Youden index on the ROC curves.

Figure legend

Figure 1

Panel A: Kaplan–Meier curve of conversion to dementia according to the tertiles of plasma P-tau181 in MCI subjects

Abbreviations: HR, hazard ratio; MCI, mild cognitive impairment.

Panel B: Associations between multiple factors and plasma P-tau181 concentrations

Forest plots of associations between demographic, comorbidities (in blue) and biological variables and plasma P-tau181 using linear regression. Means and 95% confidence intervals (CIs) are provided. Z-score are used to compare the factors between them.

Abbreviations: TIA, transient ischemic attack; APOE, apolipoprotein E; BMI, body mass index; eGFR, estimated glomerular filtration rate; MMSE, Mini–Mental State Examination.

Figure 2

Panels ABCD: Correlation between plasma P-tau181 and creatinine, eGFR, age and BMI in the amyloid negative and positive populations.

Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate.

Panels EF: Levels of plasma P-tau181 in the amyloid negative and positive populations by tertile of creatinine and eGFR

Concentrations of plasma P-tau181 between amyloid negative and positive patients were in all cases significantly different as tested using a Mann-Whitney test (P<0.05).

Abbreviations: eGFR, estimated glomerular filtration rate (unit: mL/min/1·73m2).

References

1. Lee M, Whitsel E, Avery C, et al. Variation in Population Attributable Fraction of Dementia Associated With Potentially Modifiable Risk Factors by Race and Ethnicity in the US. *JAMA Netw Open* 2022; **5**(7): e2219672.

2. Piton M, Hirtz C, Desmetz C, et al. Alzheimer's Disease: Advances in Drug Development. *Journal of Alzheimer's disease : JAD* 2018; **65**(1): 3-13.

3. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia* 2018; **14**(4): 535-62.

4. Dumurgier J, Schraen S, Gabelle A, et al. Cerebrospinal fluid amyloid-beta 42/40 ratio in clinical setting of memory centers: a multicentric study. *Alzheimer's research & therapy* 2015; **7**(1): 30.

5. Gabelle A, Dumurgier J, Vercruysse O, et al. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. *Journal of Alzheimer's disease : JAD* 2013; **34**(1): 297-305.

6. Hanon O, Vidal JS, Lehmann S, et al. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2022.

7. Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer's disease. *Alzheimer's research & therapy* 2013; **5**(2): 9.

8. Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2018; **14**(8): 989-97.

9. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *The Lancet Neurology* 2020; **19**(5): 422-33.

10. McGrath ER, Beiser AS, O'Donnell A, et al. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults. *Journal of Alzheimer's disease : JAD* 2022; **87**(4): 1517-26.

11. Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. *Molecular psychiatry* 2021; **26**(2): 429-42.

12. Clark C, Lewczuk P, Kornhuber J, et al. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. *Alzheimer's research & therapy* 2021; **13**(1): 65.

13. Chen SD, Huang YY, Shen XN, et al. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease. *Translational psychiatry* 2021; **11**(1): 356.

14. Hanon O, Vidal JS, Lehmann S, et al. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2018; **14**(7): 858-68.

15. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Archives of neurology* 1999; **56**(3): 303-8.

16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**(9): 604-12.

17. Lehmann S, Delaby C, Boursier G, et al. Relevance of Abeta42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. *Frontiers in aging neuroscience* 2018; **10**: 138.

18. Rissin DM, Walt DR. Digital concentration readout of single enzyme molecules using femtoliter arrays and Poisson statistics. *Nano Lett* 2006; **6**(3): 520-3.

19. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* 2008; **27**(2): 157-72; discussion 207-12.

20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 1988; **44**(3): 837-45.

21. Delaby C, Alcolea D, Hirtz C, et al. Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. *J Neural Transm (Vienna)* 2022.

22. Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. *Nature medicine* 2022.

23. Syrjanen JA, Campbell MR, Algeciras-Schimnich A, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2022; **18**(6): 1128-40.

24. Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. *The Lancet Neurology* 2021; **20**(9): 739-52.

25. Bayoumy S, Verberk IMW, den Dulk B, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. *Alzheimer's research & therapy* 2021; **13**(1): 198.

26. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. *Nature medicine* 2020; **26**(3): 387-97.

27. Benussi A, Karikari TK, Ashton N, et al. Diagnostic and prognostic value of serum NfL and p-Tau(181) in frontotemporal lobar degeneration. *Journal of neurology, neurosurgery, and psychiatry* 2020; **91**(9): 960-7.

28. Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. *The Lancet Neurology* 2022; **21**(3): 246-57.

29. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Cerebrospinal fluid tau levels increase with age in healthy individuals. *Dementia and geriatric cognitive disorders* 2001; **12**(2): 127-32.

30. Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. *Brain : a journal of neurology* 2022.

31. Julian BA, Suzuki H, Suzuki Y, Tomino Y, Spasovski G, Novak J. Sources of Urinary Proteins and their Analysis by Urinary Proteomics for the Detection of Biomarkers of Disease. *Proteomics Clinical applications* 2009; **3**(9): 1029-43.

32. Chan HN, Xu D, Ho SL, Wong MS, Li HW. Ultra-sensitive detection of protein biomarkers for diagnosis of Alzheimer's disease. *Chem Sci* 2017; **8**(5): 4012-8.

33. Sun R, Wang H, Shi Y, et al. A Pilot Study of Urinary Exosomes in Alzheimer's Disease. *Neuro-degenerative diseases* 2019; **19**(5-6): 184-91.

Figure 1

A

Logrank test (overall difference) = 47.3. P < .0001
HR 1st vs 3rd tertile: 3.8 (2.5 to 5.8)

B

Figure 2